A Novel Indicator of Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation: Current CMV Reactivation
- 12 October 2026
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- p. e70337
Abstract
Background: Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (allo‐HCT) is a reversible event, and conventional indicators such as the simple cumulative incidence cannot reflect transitional CMVR states. We propose a novel indicator, current CMVR (cCMVR), which visualizes both the occurrence and remission of CMVR over time. Methods: To evaluate the utility of cCMVR, we analyzed 389 CMV seropositive patients who had received their first allo‐HCT. cCMVR was defined as the probability of the state where anti‐CMV drugs were administered for CMVR or CMV disease without relapse or death at any time. Results: We compared two groups with or without letermovir prophylaxis (LTV and no‐LTV groups). The 1‐, 2‐, 3‐, and 6‐month cCMVR values were 0.0%, 0.0%, 2.9%, and 2.9% in the LTV group, and 7.1%, 31.9%, 11.0%, and 0.8% in the no‐LTV group. In the LTV group, cCMVR never exceeded 10%, while in the no‐LTV group, cCMVR peaked at approximately 2 months after allo‐HCT, and fewer than 5% of patients developed CMVR after 4 months post‐HCT. Next, in the no‐LTV group, we assessed cCMVR stratified according to the presence of risk factors for the simple cumulative incidence of CMVR, and this revealed that patients grafted from HLA‐mismatched related donors and those who received alemtuzumab for GVHD prophylaxis appeared to experience repeated episodes of CMVR, whereas the early difference in cCMVR according to pretransplant CMV‐IgG titer diminished over time. Conclusion: cCMVR could be a valuable indicator for visualizing recurrent CMV infection and illustrating differences in the time course of CMVR.Keywords
This publication has 39 references indexed in Scilit:
- Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infectionAnnals of Hematology, 2023
- Risk factors for late cytomegalovirus infection after completing letermovir prophylaxisInternational Journal of Hematology, 2022
- Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free SurvivalTransplantation and Cellular Therapy, 2021
- Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2021
- Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivationTransplantation and Cellular Therapy, 2020
- Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant SuccessTransplantation and Cellular Therapy, 2018
- Current Graft-versus-Host Disease–Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic TransplantTransplantation and Cellular Therapy, 2017
- Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological statusClinical Microbiology and Infection, 2016
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Decreased incidence of acute graft‐versus‐host disease by continuous infusion of cyclosporine with a higher target blood levelAmerican Journal of Hematology, 2007